Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials

To assess ultra-high (UH; PSA ≥  50 ng/ml) patient outcomes compared to other high risk patients and to identify outcome predictors.

read more